查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1683393

全球泌尿科機器人設備市場 - 2025 至 2033 年

Global Urology Robotics Devices Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球泌尿科機器人設備市場規模達到 67.2 億美元，預計到 2033 年將達到 285.7 億美元，在 2025-2033 年預測期內的複合年成長率為 17.7%。

泌尿科機器人設備是先進的手術工具，用於協助外科醫生對泌尿系統（包括膀胱、腎臟、前列腺和其他相關器官）進行微創手術。這些設備通常由配備專門儀器的機械手臂、用於增強可視化的高清 3D 攝影機以及外科醫生可以精確控制系統的控制台組成。

這些設備可以實現更小的切口、更快的恢復時間、更少的失血和最小的疤痕，從而改善患者的治療效果，同時保持精細的泌尿外科手術的高精度。

市場動態：

促進因素與約束因素

技術進步

技術進步透過提高泌尿科手術的精確度、效率和結果，大大推動了泌尿科機器人設備市場的發展。透過增強型機器人系統等創新提供更好的視覺化、微創技術和即時資料分析，外科醫生可以更準確、更有控制力地執行複雜的手術。這些進步縮短了患者的恢復時間，最大限度地減少了併發症，並改善了整體手術效果，使機器人設備成為泌尿外科越來越受歡迎的選擇。例如，2024 年 9 月，泌尿科機器人設備市場宣布了一項突破性進展，機器人能量療法領域的全球領導者 EDAP TMS SA 與領先的人工智慧醫療保健公司 Avenda Health 達成合作協議，以徹底改變前列腺癌治療。透過將 Avenda 的創新 AI 技術 Unfold AI 與 EDAP TMS 的尖端 Focal One 機器人高強度聚焦超音波 (HIFU) 系統相結合，兩家公司將推出世界上首個 AI 輔助機器人 HIFU 程式。

此外，這些設備中人工智慧和機器學習的整合可以實現個人化的治療計劃，進一步促進機器人技術在泌尿科護理中的應用。因此，泌尿科機器人設備的需求快速成長，進而帶來市場擴張和技術突破。

嚴格的監管框架

醫療器材（尤其是機器人系統）的核准過程複雜且耗時，通常需要進行大量臨床試驗、安全評估以及遵守區域和國際標準。這可能會導致產品發布延遲和開發成本增加。因此，這些規定可能會減緩市場擴張，並降低泌尿科新興尖端機器人技術的整體可用性。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動態

  • 影響因素
    • 驅動程式
      • 技術進步
      • 泌尿系統疾病盛行率不斷上升
    • 限制
      • 嚴格的監管框架
      • 訓練有素的專業人員數量有限
    • 機會
      • 策略夥伴關係和合作
    • 影響分析

第5章：產業分析

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 6 章：依產品類型

  • 機器人手術系統
  • 儀器及配件
  • 其他

第 7 章：按程序

  • 機器人攝護腺切除手術
  • 機器人膀胱切除術
  • 機器人腎盂成形術
  • 機器人腎臟切除手術

第 8 章：按最終用戶

  • 醫院
  • 專科診所
  • 其他

第9章：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 併購分析

第 11 章：公司簡介

  • Intuitive Surgical
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 主要進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • Asensus Surgical US, Inc.
  • MicroPort Scientific Corporation
  • Titan Medical Inc.
  • Ethicon, Inc.
  • Medtronic
  • CMR Surgical Ltd

第 12 章：附錄

簡介目錄
Product Code: MD9342

The global urology robotics devices market reached US$ 6.72 billion in 2024 and is expected to reach US$ 28.57 billion by 2033, growing at a CAGR of 17.7% during the forecast period 2025-2033.

Urology robotic devices are advanced surgical tools used to assist surgeons in performing minimally invasive procedures on the urinary system, including the bladder, kidneys, prostate, and other related organs. These devices typically consist of robotic arms equipped with specialized instruments, a high-definition 3D camera for enhanced visualization, and a console where the surgeon can control the system with precision.

These devices allow for smaller incisions, faster recovery times, reduced blood loss, and minimal scarring, improving patient outcomes while maintaining high levels of precision in delicate urological surgeries.

Market Dynamics: Drivers & Restraints

Technological Advancements

Technological advancements are significantly driving the urology robotic devices market by improving the precision, efficiency, and outcomes of urological procedures. With innovations like enhanced robotic systems offering better visualization, minimally invasive techniques, and real-time data analytics, surgeons can perform complex procedures with greater accuracy and control. These advancements reduce patient recovery times, minimize complications, and improve overall surgical outcomes, making robotic devices an increasingly popular choice in urology. For instance, in September 2024, A groundbreaking advancement in the urology robotic devices market was announced as EDAP TMS SA, a global leader in robotic energy-based therapies, and Avenda Health, a leading AI healthcare company, have entered into a collaboration agreement to revolutionize prostate cancer care. By integrating Avenda's innovative AI technology, Unfold AI, with EDAP TMS's cutting-edge Focal One robotic high-intensity focused ultrasound (HIFU) system, the companies are set to launch the world's first AI-assisted robotic HIFU procedures.

Additionally, the integration of artificial intelligence and machine learning in these devices allows for personalized treatment plans, further boosting the adoption of robotic technologies in urological care. As a result, the demand for urology robotic devices is rapidly growing, leading to market expansion and technological breakthroughs.

Stringent Regulatory Frameworks

The approval process for medical devices, especially robotic systems, is complex and time-consuming, often requiring extensive clinical trials, safety evaluations, and compliance with regional and international standards. This can lead to delays in product launches and increased development costs. As a result, these regulations can slow market expansion and reduce the overall availability of new, cutting-edge robotic technologies in urology.

Segment Analysis

The global urology robotics devices market is segmented based on the product type, procedure, end-user and region.

Robotic surgery systems segment in the product type is expected to dominate the urology robotics devices market

The robotic surgery systems segment is dominating the urology robotic devices market due to several key factors. Robotic surgery systems offer significant advantages in precision, control, and minimally invasive procedures, which are crucial for complex urological surgeries. These systems allow for enhanced visualization, reduced risk of human error, and quicker recovery times for patients, making them highly attractive to healthcare providers.

As the technology continues to evolve, robotic surgery systems are becoming more sophisticated, offering better outcomes and driving higher adoption rates across hospitals and surgical centers. For instance, in July 2024, Asensus Surgical, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an expanded indication to treat both adult and pediatric urology patients with the Senhance Surgical System. This expansion highlights the growing dominance of the robotic surgery systems segment, as the Senhance system's advanced technology enables more precise, minimally invasive procedures in urology. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to dominate the urology robotics devices market

North America is dominating the urology robotic devices market due to several key factors. The region has a strong healthcare infrastructure with advanced medical facilities and a high adoption rate of cutting-edge technologies, including robotic surgery systems. Hospitals and surgical centers in North America are more likely to invest in expensive robotic systems due to their ability to improve patient outcomes, reduce recovery times, and minimize surgical complications.

Furthermore, North America has a well-established reimbursement structure for robotic surgeries, making it financially feasible for healthcare providers to adopt these technologies. Companies are receiving FDA approvals for their advanced innovations which are driving the region's market growth.

For instance, in July 2024, Asensus Surgical, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the indication of its Senhance Surgical System to treat both adult and pediatric urology patients. This approval reflects the region's continuous innovation and adoption of advanced medical technologies, positioning North America at the forefront of robotic-assisted surgery. North America remains a global leader in transforming healthcare through robotics, setting new standards for precision, efficiency, and patient outcomes in urological care. The region also benefits from a large, aging population with an increasing demand for urological procedures, further fueling the growth of robotic devices.

Competitive Landscape

The global market players in the urology robotics devices market are Intuitive Surgical, Asensus Surgical US, Inc., MicroPort Scientific Corporation, Titan Medical Inc., Ethicon, Inc., Medtronic and CMR Surgical Ltd., among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global urology robotics devices market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Procedure
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancements in Technology
      • 4.1.1.2. Increasing Prevalence of Urological Disorders
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Frameworks
      • 4.1.2.2. Limited Availability of Trained Professionals
    • 4.1.3. Opportunities
      • 4.1.3.1. Strategic Partnerships and Collaborations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Robotic Surgery Systems*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Instruments and Accessories
  • 6.4. Others

7. By Procedure

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Robotic Prostatectomy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Robotic Cystectomy
  • 7.4. Robotic Pyeloplasty
  • 7.5. Robotic Nephrectomy

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Specialty Clinics
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Mexico
      • 9.4.6.2. Brazil
      • 9.4.6.3. Argentina
      • 9.4.6.4. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Intuitive Surgical*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Asensus Surgical US, Inc.
  • 11.3. MicroPort Scientific Corporation
  • 11.4. Titan Medical Inc.
  • 11.5. Ethicon, Inc.
  • 11.6. Medtronic
  • 11.7. CMR Surgical Ltd

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us